Fusidic Acid 1% not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Bacterial Conjunctivitis
- Main trialPhase 3
- “The purpose of this clinical trial is to demonstrate the superiority of fusidic acid 1% over placebo in adults and children with confirmed bacterial conjunctivitis and to further establish the safety profile of fusidic acid 1% for topical ocular administration.”In the company’s words, NCT06911424 on ClinicalTrials.gov
Other drugs for Bacterial Conjunctivitis
- SUM-191Senju USA, Inc. · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 16 Mar 2026 | Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026